Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study (Induction Therapy) & Long-term Extension Therapy of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderately Active UC

NCT02647866 is registered in ClinicalTrials.gov with Kyowa Kirin, Inc. as lead sponsor.

NCT NCT02647866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02647866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study (Induction Therapy) & Long-term Extension Therapy of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderately Active UC
Lead sponsor
Kyowa Kirin, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2016
Completion date
October 31, 2018
Enrollment
66 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

abdominal pain, autoimmune disease, colitis, colitis, ulcerative, colonic diseases, digestive system diseases, gastrointestinal diseases, inflammatory bowel diseases, intestinal diseases, ulcerative colitis